Science Applications International stock has delivered a 50.4% total return over the past five years, yet current valuation checks still lean toward the shares looking inexpensive rather than fully priced in. With the stock recently at US$115.72 and fresh contract wins in hand, investors are weighing how much of that long term performance is already reflected in today’s price.

• Over the last five years, Science Applications International has returned 50.4%, which points to solid long term value creation for shareholders.
• The new US$70 million U.S. Navy radar engineering task order can support revenue visibility and contract momentum, while reliance on government spending and contract renewals may limit how much investors are willing to pay for the stock.
• Science Applications International screens as undervalued on 5 out of 6 checks, which suggests the broader valuation work still leans toward the stock being cheap rather than expensive on fundamentals.

The issue now is whether that apparent discount offers enough margin of safety after the gains already delivered by Science Applications International.

Is Science Applications International a Bargain on Earnings?

The P/E ratio fits Science Applications International well because earnings are a key driver of how investors judge a mature government services contractor. The stock trades on a P/E of about 12.1x, which is well below both the Professional Services industry average of 23.2x and a peer average of 21.5x. That already points to the market applying a clear discount to Science Applications International versus similar companies.

A more tailored yardstick, which looks at the company’s earnings profile and risk factors, suggests a fair P/E of about 15.5x. Compared with the current 12.1x, that indicates the shares trade at a material gap to what this model would expect if Science Applications International were valued in line with those characteristics. Despite the recent US$70 million U.S. Navy radar task order that supports the contract pipeline, the market multiple still prices the stock below sector norms.

On the P/E multiple, Science Applications International stock currently appears undervalued relative to both its tailored fair ratio and industry benchmarks.

The Science Applications International Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Science Applications International leaves off. They spell out what would need to happen to the company’s growth, margins and earnings for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St’s Community page. Each one ties a fair value estimate to a specific storyline about Science Applications International's potential catalysts and risks so you can track which version of events is unfolding over time.

Community views on Science Applications International sit far apart, with one camp focused on upside from contract momentum and another watching contract risk and margins.

Bull case: 16% undervalued

"A robust backlog of over $20 billion in submitted bids, combined with consistently high contract renewal rates and new program wins, gives exceptional multi-year revenue visibility..."

Bear case: 20% overvalued

"Book-to-bill ratios remain under target, and recompete headwinds, including the loss of a substantial NASA program, may continue to pressure revenue and earnings growth..."

Do you think there's more to the story for Science Applications International? Head over to our Community to see what others are saying!

The Bottom Line

Science Applications International still screens as undervalued on its P/E against both sector averages and a tailored fair ratio, even after a multi year run that has rewarded patient holders. The core question now is whether that discount reflects genuine mispricing or a reasonable caution around government contract concentration and renewal risk. For many investors, the crux is whether contract momentum and margins hold well enough for the market to close some of that valuation gap instead of leaving the stock cheap for a reason.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.